Nantomics LLC, of Culver City, Calif., reported that research based on the company’s deep learning system has been published in a peer-reviewed journal, highlighting the algorithm’s ability to discern which mutation drives a patient’s breast cancer.

TORONTO – Kitchener, Ontario-based Nicoya Life Sciences Inc. has followed up CA$10 million (US$7.6 million) in series A funding raised in January with its launch of “the world’s first digital benchtop surface plasmon resonance (SPR) system” to boost development of drug therapies.

Nantomics LLC, of Culver City, Calif., reported that research based on the company’s deep learning system has been published in a peer-reviewed journal, highlighting the algorithm’s ability to discern which mutation drives a patient’s breast cancer. The company said their approach is a rapid and cost-effective way to establish the breast cancer subtype, thus giving clinician and patient alike a good understanding of which therapies would be ineffective for that cancer and maximizing the chances for a cure.